On January 17, 2023 – Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, reported two new collaborations with McSAF and Cristal Therapeutics to expand its bioconjugates offering (Press release, Cristal Therapeutics, JAN 17, 2023, View Source [SID1234626286]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The collaborations will enable the integration of two novel conjugation platforms, McSAF Inside and CliCr, into the Lonza Bioconjugation Toolbox. The Lonza Bioconjugation Toolbox comprises a range of tailored solutions for the technology selection, development and manufacturing of bioconjugates to advance the development of novel bioconjugate-based therapies.
Cristal Therapeutic CliCr technology is a novel class of versatile and highly reactive bioorthogonal reagents that supports the straightforward and highly-efficient generation of a large range of bioconjugates. The CliCr technology relies on metal-free click chemistry and provides improved yields and broad applicability compatible with biochemically-relevant reaction conditions.
McSAF Inside Technology allows for the fast and efficient generation of homogeneous and stable antibodydrug conjugates (ADCs) from native antibodies. The technology relies on a set of unique reagents for the sitespecific conjugation of a linker-payload to previously reduced interchain cysteines of a native antibody. Compared to conventional methods, McSAF Inside produces ADCs of high purity and stability and can support novel bioconjugates, based on antibody fragments or other therapeutic proteins that contain an accessible disulfide bond.
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates. At the same time, the collaborations build additional capabilities into Lonza’s service portfolio, furthering the development of an end-to-end bioconjugates offering that can support customers in overcoming a range of development and manufacturing challenges.
Iwan Bertholjotti, Senior Director Commercial Development, Bioconjugates, Lonza, commented: "CliCr and McSAF Inside are great additions to the Lonza Bioconjugation Toolbox, allowing us to extend our portfolio of technologies for drug developers involved in developing novel bioconjugates/ADCs. These collaborations are creating a unique industry network to facilitate the development of novel bioconjugates with potential to treat life-threatening diseases.
" Marie-Claude Viaud-Massuard, Co-Founder and Chief Scientific Officer, McSAF said: "The robustness, scalability and broad compatibility of McSAF’s technology enabled a successful transfer to the Lonza team. Choosing McSAF’s technology provides a high degree of flexibility, allowing the combination of multiple proteins and linker-payloads in order to optimize and select the best candidate. In addition, customers will mitigate the risk associated with CMC stages through Lonza’s expertise and their understanding of McSAF know-how."
Werner Cautreels, CEO, Cristal Therapeutics added: "CliCr is a powerful metal-free click chemistry technology for the life science industry which offers shorter reaction times and greater yields and hence attractive CoG than comparative reagents on the market. Our collaboration with Lonza will help to extend the impact of this innovative technology for use in straightforward bioconjugation in a plethora of important applications in therapeutic or diagnostic products. "